KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Receivables - Net: 2020-2022

Historic Receivables - Net for Recursion Pharmaceuticals (RXRX) over the last 1 years, with Jun 2022 value amounting to $21,000.

  • Recursion Pharmaceuticals' Receivables - Net fell 57.14% to $21,000 in Q2 2022 from the same period last year, while for Jun 2022 it was $21,000, marking a year-over-year decrease of 57.14%. This contributed to the annual value of $34,000 for FY2021, which is 78.21% down from last year.
  • As of Q2 2022, Recursion Pharmaceuticals' Receivables - Net stood at $21,000, which was down 38.24% from $34,000 recorded in Q1 2022.
  • Recursion Pharmaceuticals' 5-year Receivables - Net high stood at $156,000 for Q4 2020, and its period low was $21,000 during Q2 2022.
  • Over the past 3 years, Recursion Pharmaceuticals' median Receivables - Net value was $34,000 (recorded in 2022), while the average stood at $57,000.
  • Data for Recursion Pharmaceuticals' Receivables - Net shows a maximum YoY plummeted of 78.21% (in 2021) over the last 5 years.
  • Quarterly analysis of 3 years shows Recursion Pharmaceuticals' Receivables - Net stood at $156,000 in 2020, then crashed by 78.21% to $34,000 in 2021, then slumped by 57.14% to $21,000 in 2022.
  • Its Receivables - Net was $21,000 in Q2 2022, compared to $34,000 in Q1 2022 and $34,000 in Q4 2021.